Controversies in clinical cancer dormancy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 30, 2011, Pages 12396-12400

  Uhr, Jonathan W ^a   Pantel, Klaus ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chronic cancer; Circulating tumor cell; Organ size control

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RELAPSE; CANCER STEM CELL; CIRCULATING TUMOR CELL; CLINICAL CANCER DORMANCY; DISEASE FREE INTERVAL; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VIRUS CARCINOGENESIS; WART VIRUS;

ADAPTIVE IMMUNITY; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; MALE; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECURRENCE; TIME FACTORS;

EID: 79961087495     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1106613108     Document Type: Article

References (80)

1. White EG (1864) An Appeal to Mothers (Seventh-Day Adventist Publishing Assoc, Battle Creek, MI).
2. Dao TL, Sunderland H (1959) Mammary carcinogenesis by 3-methylcholanthrene. I. Hormonal aspects in tumor induction and growth. J Natl Cancer Inst 23:567-585.
3. Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80-85. (Pubitemid 29042447)
4. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746. (Pubitemid 26329660)
5. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Res Treat 41:177-185. (Pubitemid 26360147)
6. Demicheli R (2001) Tumour dormancy: Findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 11:297-306.
7. Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. Science 241:58-62.
8. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329-340. (Pubitemid 351596394)
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
10. Pantel K, et al. (1993) Differential expression of proliferation- associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424. (Pubitemid 23264351)
11. Uhr JW, Scheuermann RH, Street NE, Vitetta ES (1997) Cancer dormancy: Opportunities for new therapeutic approaches. Nat Med 3:505-509. (Pubitemid 27198646)
12. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834-846.
13. Brackstone M, Townson JL, Chambers AF (2007) Tumour dormancy in breast cancer: An update. Breast Cancer Res 9:208.
14. Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour dormancy. APMIS 116:754-770.
15. Wicha MS (2006) Cancer stem cells and metastasis: Lethal seeds. Clin Cancer Res 12:5606-5607.
16. Balic M, et al. (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615-5621. (Pubitemid 44629587)
17. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12:863-879. (Pubitemid 33051984)
18. Meng S, et al. (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152-8162. (Pubitemid 40053373)
19. Thomas L (1959) Discussion. Cellular and Humoral Aspects of the Hypersensitive States, ed Lawrence H (Hoeber-Harper, New York), pp 529-532.
20. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1-27.
21. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360. (Pubitemid 38680426)
22. Koebel CM, et al. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907. (Pubitemid 350231320)
23. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ (2008) Immune-mediated dormancy: An equilibrium with cancer. J Leukoc Biol 84:988-993.
24. Rosenberg SA, et al. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166. (Pubitemid 24249302)
25. Aebersold P, et al. (1991) Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response. J Natl Cancer Inst 83:932-937.
26. Vajdic CM, et al. (2006) Cancer incidence before and after kidney transplantation. JAMA 296:2823-2831. (Pubitemid 44969182)
27. Penn I (2000) Post-transplant malignancy: The role of immunosuppression. Drug Saf 23:101-113.
28. Chapman JR, Sheil AG, Disney AP (2001) Recurrence of cancer after renal transplantation. Transplant Proc 33:1830-1831. (Pubitemid 32238082)
29. Stein A, Wild J (2002) Kidney Failure Explained (Class, London), 2nd Ed.
30. Stewart JH, et al. (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: Analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14:197-207. (Pubitemid 36026310)
31. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137-1146. (Pubitemid 46718398)
32. Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530. (Pubitemid 13160576)
33. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141-146. (Pubitemid 41613441)
34. Shankaran V, et al. (2001) IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111. (Pubitemid 32391043)
35. Airoldi I, et al. (2005) Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106:3846-3853. (Pubitemid 41739022)
36. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW, IV (2003) STAT1-dependent innate immunity to a Norwalk-like virus. Science 299:1575-1578. (Pubitemid 36297707)
37. Enzler T, et al. (2003) Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J Exp Med 197:1213-1219. (Pubitemid 36570077)
38. Rothfuchs AG, et al. (2006) STAT1 regulates IFN-αβ- and IFN-γ-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells. J Immunol 176:6982-6990. (Pubitemid 43787878)
39. Stills HF, Jr. (2005) Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 46:280-293.
40. Lollini PL, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6:204-216. (Pubitemid 43292564)
41. Timmerman JM, et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99:1517-1526. (Pubitemid 34533020)
42. Stevenson FK, George AJ, Glennie MJ (1990) Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol 48:126-166. (Pubitemid 20033443)
43. Uhr JW, Tucker T, May RD, Siu H, Vitetta ES (1991) Cancer dormancy: Studies of the murine BCL1 lymphoma. Cancer Res 51(Suppl 18):5045s-5053s.
44. Racila E, et al. (1995) Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 181:1539-1550.
45. Marches R, Hsueh R, Uhr JW (1999) Cancer dormancy and cell signaling: Induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc Natl Acad Sci USA 96:8711-8715. (Pubitemid 29354856)
46. Galon J, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964. (Pubitemid 44498003)
47. Zippelius A, et al. (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 64:2865-2873. (Pubitemid 38500627)
48. Chen ML, et al. (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 102:419-424.
49. Kantoff PW, et al.; IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422.
50. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
51. DuPage M, et al. (2011) Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19:72-85.
52. Almog N, et al. (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69:836-844.
53. Folkman J, Kalluri R (2004) Cancer without disease. Nature 427:787. (Pubitemid 38297724)
54. Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5:1744-1750. (Pubitemid 44435316)
55. Willis L, et al. (2010) Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 70:4310-4317.
56. Potter CJ, Xu T (2001) Mechanisms of size control. Curr Opin Genet Dev 11:279-286. (Pubitemid 32480294)
57. Klein CA, Hölzel D (2006) Systemic cancer progression and tumor dormancy: Mathematical models meet single cell genomics. Cell Cycle 5:1788-1798. (Pubitemid 44435321)
58. Noble RL, Hochachka BC, King D (1975) Spontaneous and estrogen-produced tumors in Nb rats and their behavior after transplantation. Cancer Res 35:766-780.
59. Senior PV, Murphy P, Alexander P (1985) Estrogen-dependent rat mammary carcinoma as a model for dormant metastases. Treatment of Metastases: Problems and Prospects, eds Hellmann K, Eccles SA (Taylor and Francis, Philadelphia), pp 169-173.
60. Chambers AF (2009) Influence of diet on metastasis and tumor dormancy. Clin Exp Metastasis 26:61-66.
61. Yu W, Kim J, Ossowski L (1997) Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 137:767-777. (Pubitemid 27200676)
62. Aguirre Ghiso JA (2002) Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21:2513-2524.
63. Conlon I, Raff M (1999) Size control in animal development. Cell 96:235-244. (Pubitemid 29059353)
64. Day SJ, Lawrence PA (2000) Measuring dimensions: The regulation of size and shape. Development 127:2977-2987. (Pubitemid 30611891)
65. Hall MN, Raff M, Thomas G (2004) Cell Growth: Control of Cell Size (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY).
66. Michalopoulous GK, DeFrances M (1977) Liver regeneration. Science 29:60-63.
67. Verdu J, Buratovich MA, Wilder EL, Birnbaum MJ (1999) Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat Cell Biol 1:500-506. (Pubitemid 129503670)
68. Renehan AG, et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 363:1346-1353. (Pubitemid 38529873)
69. Grimberg A, Cohen P (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9. (Pubitemid 30130219)
70. Moschos SJ, Mantzoros CS (2002) The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 63:317-332. (Pubitemid 36151524)
71. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857. (Pubitemid 34048651)
72. Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8:BR521-BR526. (Pubitemid 36119174)
73. Hongo A, et al. (2003) Antitumor effects of a soluble insulin-like growth factor I receptor in human ovarian cancer cells: Advantage of recombinant protein administration in vivo. Cancer Res 63:7834-7839. (Pubitemid 37466716)
74. Thomas LN, Wright AS, Lazier CB, Cohen P, Rittmaster RS (2000) Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factorbinding proteins (IGFBPs)-2, -4, and -5. Prostate 42:203-210. (Pubitemid 30080419)
75. Zaina S, Squire S (1998) The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. J Biol Chem 273:28610-28616. (Pubitemid 28507544)
76. Böhni R, et al. (1999) Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell 97:865-875. (Pubitemid 29375046)
77. Gao X, et al. (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704. (Pubitemid 34993706)
78. Pan D (2007) Hippo signaling in organ size control. Genes Dev 21:886-897.
79. Wu S, Huang J, Dong J, Pan D (2003) hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114:445-456. (Pubitemid 37100993)
80. Zhao B, Lei QY, Guan KL (2008) The Hippo-YAP pathway: New connections between regulation of organ size and cancer. Curr Opin Cell Biol 20:638-646.